By modulating mitochondrial metabolism, it prevents the over-activation of mTOR , a key nutrient sensor that, when overactive, is linked to neurodegeneration and inflammation. 🧠 Therapeutic Applications
MSDC-0160 is a novel, clinical-stage drug candidate originally developed for . It is the prototype of a new class of insulin sensitizers called mTOT Modulators (Mitochondrial Target of Thiazolidinediones). Unlike first-generation insulin sensitizers like pioglitazone, MSDC-0160 is PPAR msdc 0160 buy
MSDC-0160 works by selectively binding to and inhibiting the , a protein complex in the inner mitochondrial membrane. By modulating mitochondrial metabolism